How the IMB monitors product safety
The Irish Medicines Board uses a variety of methods to collect information on the safety and quality of medicinal and healthcare products.
Pharmaceutical companies are obliged, under the conditions of authorisation to market their medicinal products in Ireland, to submit adverse reactions associated with use of their products to the IMB. In addition, healthcare professionals and consumers are encouraged to report any suspected adverse reaction associated with a medicinal product to the IMB.
The Market Compliance Section also receives and assesses complaints and reports of actual or suspected quality defects in medicines.
Medical devices are extremely diverse and we use in-house specialist knowledge, comprehensive information systems and access to up-to-date external advice to issue appropriate advice. This may address device or user-related issues, or both.